Operating income before deduction of amortization: Acasti Pharma Inc. (ACST)

Acasti Pharma (ACST) is mitigating regulatory threats by diversifying its portfolio of orphan drugs for rare pathologies. The company's revenues are based on licensing and the development of unique pharmaceuticals. Monitoring of EBITDA_Co reveals volatility in operating flows, while the value of shows the most recent figure. The expected launch of final trials for neurovascular agents serves as the primary driver, and current market quotes already price in high operational risks.

For the small biotech company Acasti Pharma (ACST), whose prospects depend on the outcome of final clinical trials, controlling operational survival is critical. This metric measures the actual cash inflow from core activities, allowing investors to use operating earnings trends to detect liquidity degradation in a timely manner and assess business resilience under high-risk conditions before drugs reach the market.